Skip to main content
Terug
TFX logo

Teleflex Incorporated

Datakwaliteit: 100%
TFX
NYSE Healthcare Medical - Instruments & Supplies
€ 105,85
▲ € 0,44 (0,42%)
Marktkapitalisatie: 4,68B
Dagbereik
€ 105,47 € 108,50
52-Weeksbereik
€ 100,18 € 143,32
Volume
634.933
50D / 200D Gem.
€ 108,90 / € 118,14
Vorige Slotkoers
€ 105,41

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -5,2 0,4
P/B 1,5 2,9
ROE % -24,5 3,7
Net Margin % -45,5 3,9
Rev Growth 5Y % -8,2 10,0
D/E 0,9 0,2

Koersdoel Analisten

Hold
€ 133,25 +25.9%
Low: € 116,00 High: € 147,00
Forward K/W
14,3
Forward WPA
€ 7,43
WPA Groei (sch.)
+0,0%
Omzet Sch.
2,4 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 11,07
€ 11,00 – € 11,17
2,8 B 1
FY2029 € 10,04
€ 9,97 – € 10,13
2,7 B 1
FY2028 € 11,76
€ 11,68 – € 11,86
2,5 B 1

Belangrijkste Punten

Revenue declined -8,23% annually over 5 years
Earnings declined -1399,81% over the past year
Generating 245,44M in free cash flow
PEG of 0,00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 26,38%
Capital efficient — spends only 4,78% of revenue on capex

Groei

Revenue Growth (5Y)
-8,23%
Revenue (1Y)-34,61%
Earnings (1Y)-1399,81%
FCF Growth (3Y)-23,48%

Kwaliteit

Return on Equity
-24,47%
ROIC3,28%
Net Margin-45,45%
Op. Margin12,84%

Veiligheid

Debt / Equity
0,87
Current Ratio2,54
Interest Coverage2,55

Waardering

P/E Ratio
-5,17
P/B Ratio1,50
EV/EBITDA27,41
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -34,61% Revenue Growth (3Y) -18,15%
Earnings Growth (1Y) -1399,81% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -8,23% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,99B Net Income (TTM) -905,64M
ROE -24,47% ROA -13,04%
Gross Margin 56,24% Operating Margin 12,84%
Net Margin -45,45% Free Cash Flow (TTM) 245,44M
ROIC 3,28% FCF Growth (3Y) -23,48%
Safety
Debt / Equity 0,87 Current Ratio 2,54
Interest Coverage 2,55 Dividend Yield 0,01%
Valuation
P/E Ratio -5,17 P/B Ratio 1,50
P/S Ratio 2,35 PEG Ratio 0,00
EV/EBITDA 27,41 Dividend Yield 0,01%
Market Cap 4,68B Enterprise Value 7,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,99B 3,05B 2,97B 2,79B 2,81B
Net Income -905,64M 69,68M 356,33M 363,14M 485,37M
EPS (Diluted) -20,25 1,48 7,53 7,68 10,23
Gross Profit 1,12B 1,70B 1,65B 1,53B 1,55B
Operating Income 255,80M 151,01M 506,31M 499,73M 628,10M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,95B 7,10B 7,53B 6,93B 6,87B
Total Liabilities 3,82B 2,82B 3,09B 2,91B 3,12B
Shareholders' Equity 3,12B 4,28B 4,44B 4,02B 3,75B
Total Debt 2,73B 1,76B 1,93B 1,83B 1,97B
Cash & Equivalents 393,26M 290,19M 222,85M 292,03M 445,08M
Current Assets 1,94B 1,47B 1,41B 1,41B 1,43B
Current Liabilities 762,03M 649,36M 606,75M 581,49M 680,12M